Pharma: Clinic Roundup
Wednesday, May 23, 2012
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said results from the pivotal Phase III GEMINI trial showed that, after six weeks of induction therapy, 47. 1 percent of patients with moderately to severely active ulcerative colitis who received gut-selective monoclonal antibody vedolizumab experienced clinical response vs. 25.5 percent in the placebo group (p < 0.0001).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.